LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Longeveron Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$1.39+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $43.61M
P/E (TTM): –
Dividend yield: –

Dividends

Longeveron has not reported a dividend

No dividend per share appears in Longeveron's annual filings since fiscal 2019.

Where these numbers come from

Parsed from the XBRL in Longeveron's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Aug 27, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LGVN.

Revenue growth-42.7% · median -5.0%

Operating margin-1992.8% · median -2202.4%

Net margin-1977.6% · median -2134.3%

Company	Revenue	Growth
RNAC	$1.48M	–
LGVN	$1.19M	-42.7%
IGC	$1.12M	-15.4%
MNOV	$920.48K	–
VCNX	$601.00K	+5.4%
XCUR	$0	–

Company

Next earnings (est.): Nov 3, 2026, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 37
Auditor: Marcum LLPMarcum LLP
SEC CIK: 1721484

Advertisement
300 × 250